Schick Kelly 4
4 · C4 Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
C4 Therapeutics CPO Schick Kelly Receives RSU Award and Vests Shares
What Happened
Schick Kelly, Chief People Officer at C4 Therapeutics (CCCC), received a grant of 200,000 restricted stock units (RSUs) and had previously granted RSUs vest/convert into 25,950 shares on Feb 13–14, 2026. The RSU grant shows an acquisition price of $0 (standard for RSUs). The company withheld 1,735 and 7,269 shares on the two vesting events to satisfy tax-withholding obligations (codes F), valued at $1.89 per share (total withheld value $17,017). Net shares delivered to Kelly after withholding were 16,946.
Key Details
- Transaction dates: Feb 13, 2026 (200,000 RSU grant; 5,000 RSUs converted) and Feb 14, 2026 (20,950 RSUs converted). Form filed Feb 18, 2026.
- Transaction codes: A = award/grant (200,000 RSUs); M = conversion/exercise of derivative (25,950 shares acquired on conversion); F = shares withheld for taxes (1,735 and 7,269 shares).
- Prices/values: RSUs granted/converted at $0 (grant price); withholding valued at $1.89/share — $3,279 and $13,738 respectively (total $17,017).
- Net shares received after withholding: 25,950 vested → 9,004 withheld → 16,946 net shares.
- Footnotes: F1 details future vesting schedule for the 200,000 RSUs (100,000 vest in three equal annual installments beginning Feb 13, 2027; 100,000 vest in full on Feb 13, 2029 subject to performance). F2 notes the converted shares came from previously disclosed RSU grants (originally reported 2023–2025). F3 clarifies withheld shares are for tax withholding and are not sales by the reporting person.
- Filing timeliness: Form filed Feb 18 covering Feb 13–14 transactions; the filing date is shown on the report provided. (No late-filing flag was included in the provided data.)
Context
- These transactions are largely routine equity compensation events: an RSU grant plus the vesting/settlement of RSUs with company withholding to cover taxes. The conversion/exercise entries reflect RSUs settling into shares rather than a cash purchase.
- Withheld shares (code F) are not open-market sales by the insider and should not be interpreted as a sell signal. Purchases would generally be more indicative of insider bullishness; this filing documents compensation and tax withholding.
Insider Transaction Report
Form 4
Schick Kelly
Chief People Officer
Transactions
- Award
Common Stock
[F1]2026-02-13+200,000→ 308,885 total - Exercise/Conversion
Common Stock
[F2]2026-02-13+5,000→ 308,885 total - Tax Payment
Common Stock
[F3]2026-02-13$1.89/sh−1,735$3,279→ 307,150 total - Exercise/Conversion
Common Stock
[F2]2026-02-14+20,950→ 307,150 total - Tax Payment
Common Stock
[F3]2026-02-14$1.89/sh−7,269$13,738→ 299,881 total
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
- [F2]Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.
- [F3]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Signature
/s/ Shagha Russell, Attorney-in-Fact|2026-02-18